

10/566856

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV710216005US, on the date shown below in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: January 30, 2006

Signature:

Ava R. Brown
(Ava R. Brown)

AP20 Rec'd PCT/PTO 30 JAN 2006

Docket No.: 17243/004001
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Heinz W. Gschwend et al.

Application No.: National Phase of
PCT/US2004/024541

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: PYRIDAZINE DERIVATIVES AND THEIR
USE AS THERAPEUTIC AGENTS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and

10/566856

Application No.: National Phase of PCT/US2004/024541

1AP20 Rec'd PCT/PTO 30 JAN 2006

Docket No.:

Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-0591, under Order No. 17243/004001.

Dated: January 30, 2006

Respectfully submitted,

By 

T. Chyau Liang, Ph.D.
Registration No.: 48,885
OSHA · LIANG LLP
1221 McKinney St., Suite 2800
Houston, Texas 77010
(713) 228-8600
(713) 228-8778 (Fax)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known 2 3 4 5 6			
		Application Number	Not Yet Assigned		
		Filing Date	Concurrently Herewith		
		First Named Inventor	Heinz W. Gschwend		
		Art Unit	N/A		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	2	Attorney Docket Number	17243/004001

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-2,985,657		PAUL A. JANSSEN	
	AB*	US-5,166,147	11-24-1992	Earl	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-02/102778	12-27-2002	IWATA MASAHIRO		
	BB	EP-1 396 487	03-10-2004	YAMANOUCHI PHARMA CO. LTD.		
	BC	WO-02/10154	02-07-2002	ELI LILLY AND COMPANY, ET AL.		
	BD	WO-99/00386	01-07-1999	RESOLUTION PHARMACEUTICALS INC., ET AL.		
	BE	WO-97/37975	10-16-1997	DR. KARL THOMAE GMBH		
	BF	EP-0 320 032	06-14-1989	JANSSEN PHARMACEUTICA N.V.		
	BG	EP-0 211 457	02-25-1987	JANSSEN PHARMACEUTICA N.V.		
	BH	EP-0 156 433	10-02-1985	JANSSEN PHARMACEUTICA N.V.		
	BI	WO-01/62954	08-30-2001	Univ. British Columbia		
	BJ	WO-03/076422	09-18-2003	JANSSEN PHARMACEUTICA N.V., ET AL.		
	BK	WO-03/075929	09-18-2003	Meerpoel Lieven		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with a single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Hori, T. et al.; "Studies on Antitumor-Active 2, 3-Dioxopiperazine Derivatives. III. Synthesis and Struct-Antitumor Activity Relationship of 1-(4-Aminobenzyl)-2,3-dioxopiperazine Derivatives" Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan, Tokyo, JP, Vol. 29, No. 5 (1981) (pages 1253-126)	
	CB	Steck, et al. "Pyridazines. VII. Some 3-Dialkylaminopyridazines (1)" Sterling-Winthrop Research Institute, Vol 11 (1974) (pages 1077-1079)	
	CC	Toldy, L. et al. "Piperazinderivate, I. 3, 4, 5-Trimethoxybenzoylderivate, Eine Neue Verbindungsgruppe Mit Antulzerogener Wirkung" Acta Chemica Academiae Scientiarum	
Examiner Signature		Date Considered	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	17243/004001
				Filing Date	Concurrently Herewith
				First Named Inventor	Heinz W. Gschwend
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	17243/004001

		Hungarica, Budapest, Hu., Vol 49, No. 3 (1966) (pages 265-286)	
	CD	Ratouis, et al. "Synthesis and Pharmacological Study of New Piperazine Derivatives" Vol. 8, January, 1965 (pages 104-107)	
	CE	Boissier, J. R. et al. "Synthesis and Pharmacological Study of New Piperazine Derivatives" Vol. 6 (pages 541-544)	
	CF	Database Caplus "Online! Chemical Abstracts Service, Columbus, Ohio, US; RN: 15567-65-4 1967, Toldy, et al. "Piperazine Derivatives..." retrieved from STN Database accession no. AN:1967:473577 abstract and Acta Chim.Acad.Sci.Hung., Vol. 52, No. 3 1967, pages 283-299	
	CG	Database Caplus "Online! Chemical Abstracts Service, Columbus, Ohio, US; RN: 18524-49-7 1968, Toldy, et al. "Phenothiazine drivatives..." retrieved from STN Database accession no. AN:1968:95776 abstract and Acta Chim.Acad.Sci.Hung., Vol. 53, No. 3 1967, pages 279-294	
	CH	International Search Report for PCT/US2004/024541, published February 10, 2005 (8 pages)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--